11,500,000 UNITS REGENERX BIOPHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 21st, 2010 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
RegeneRx Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), confirms its agreement, subject to the terms and conditions set forth herein, with each of the underwriters listed on Exhibit A hereto (collectively, the “Underwriters”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), to sell and issue to the Underwriters an aggregate of 11,500,000 units, each unit consisting of one (1) share of common stock, par value of $0.001 (the “Common Shares”), or 11,500,000 shares in the aggregate, and 0.4 of a tradeable warrant to purchase one Common Share, or 4,600,000 warrants in the aggregate, (the “Warrants”) of the Company (each, a “Firm Unit”). The Warrants are being issued pursuant to and shall have the rights and privileges set forth in that certain Warrant Agreement, dated as of the date hereof, between the Company and American Stock Transfer & Trust Company (the “Warrant Agree
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR...Regenerx Biopharmaceuticals Inc • May 21st, 2010 • Pharmaceutical preparations • New York
This WARRANT (this “Warrant”) of RegeneRx Biopharmaceuticals, Inc., a corporation duly organized and validly existing under the laws of the State of Delaware (the “Company”), is being issued pursuant to that certain Underwriting Agreement, dated as of May 17, 2010, by and between the Company and Maxim Group LLC, the representative of the underwriters (the “Representative”) relating to a firm commitment public offering (the “Offering”) of an aggregate of 11,500,000 units, each unit consisting of (i) one share of common stock, par value of $0.001 of the Company (each a “Common Share” and collectively, the “Common Shares”) and (ii) 0.4 Warrants to purchase one Common Share.
WARRANT AGREEMENTWarrant Agreement • May 21st, 2010 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This Warrant Agreement made as of May 21, 2010, is between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation, with offices at 15245 Shady Grove Road, Suite 470, Rockville, MD 20850 (the “Company”), and American Stock Transfer & Trust Company, LLC, with offices at 6201 15th Avenue, Brooklyn, NY (the “Warrant Agent”).
